Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.66 |
| ▸ | FABP7 | O15540 | 1/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15783737 | 1.00 | POLB (0.68) | POLBHDAC4FABP7FABP5TSHR | |
| SCHEMBL19355164 | 0.86 | POLB (0.89) | POLBHDAC4FABP7FABP5TSHR | |
| SCHEMBL14225120 | 0.86 | POLB (0.89) | POLBHDAC4FABP7FABP5TSHR | |
| SCHEMBL15769078 | 0.85 | POLB (0.70) | POLBHDAC4TSHRHDAC3HDAC7 | |
| SCHEMBL15783747 | 0.83 | FABP7 (0.60) | POLBHDAC4FABP7FABP5TSHR | |
| SCHEMBL8067771 | 0.82 | POLB (0.82) | POLBHDAC4FABP7FABP5TSHR | |
| SCHEMBL8067775 | 0.82 | POLB (0.82) | POLBHDAC4FABP7FABP5TSHR | |
| SCHEMBL16869915 | 0.81 | POLB (1.00) | POLBFABP7FABP5TSHRATM | |
| SCHEMBL16870078 | 0.81 | POLB (1.00) | POLBFABP7FABP5TSHRATM | |
| SCHEMBL16869924 | 0.81 | POLB (1.00) | POLBFABP7FABP5TSHRATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855267-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9855267-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9765054-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765054-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170042892-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042892-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042892-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9505736-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505736-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505736-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150203468-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150203468-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150203468-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014014900-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2012103008-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | POLB 252/4885HDAC4 10/4885FABP7 2220/4885 |
| US-20170042892-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | POLB 252/4885HDAC4 10/4885FABP7 2220/4885 |
| US-20150203468-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | POLB 252/4885HDAC4 10/4885FABP7 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.